SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed on April 7, 2006, reporting events occurring on April 3, 2006. The registrant is Hemispherx Biopharma, Inc., a Delaware corporation. The filing addresses a critical compliance failure regarding the listing standards of The American Stock Exchange (AMEX).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it discloses a material deficiency in financial reporting: previously issued financial statements for periods from March 31, 2003, through December 31, 2005, should not be relied upon. The company failed to file its audited Form 10-K for the fiscal year ended December 31, 2005, on a timely basis.
Material Changes and Listing Status
- Delisting Notice: On April 3, 2006, Hemispherx received notice from the AMEX of non-compliance with Sections 134 and 1101 of the AMEX Company Guide due to the failure to file the 2005 annual report.
- Trading Symbol: The company's trading symbol has been modified to include the ".LF" indicator (trading as HEB.LF) to denote non-compliance with continued listing standards.
- Financial Restatement: The company announced that all financial statements included in Forms 10-Q and 10-K from March 31, 2003, to December 31, 2005, are unreliable and require restatement.
Outlook, Management Commentary, and Risks
Management intends to file the Form 10-K for the fiscal year ended December 31, 2005, promptly after audited statements are available. Additionally, amended quarterly reports for the first three quarters of 2005 (including restated quarters for 2004) will be filed within ten business days thereafter. The company expects to regain compliance with SEC and AMEX requirements upon filing these reports.
Deadlines and Risks:
- Hemispherx must submit a compliance plan to the AMEX by April 17, 2006.
- The company must achieve full compliance with listing standards by June 2, 2006.
- Failure to meet these deadlines or provide an acceptable plan will result in the initiation of delisting proceedings.
Investor Verification Checklist
- Verify the status of the compliance plan submission to the AMEX by the April 17, 2006 deadline.
- Monitor the filing of the restated Form 10-K for 2005 and amended 10-Qs for 2005.
- Confirm whether the ".LF" trading indicator has been removed following the filing of corrected reports.
- Assess the impact of the financial restatement on the company's historical financial position and current liquidity.